- Home
- DRUG vs CLBR Comparison
DRUG vs CLBR Comparison
Compare DRUG & CLBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- CLBR
- Stock Information
- Founded
- DRUG 2019
- CLBR 2023
- Country
- DRUG United States
- CLBR United States
- Employees
- DRUG N/A
- CLBR N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- CLBR
- Sector
- DRUG Health Care
- CLBR
- Exchange
- DRUG Nasdaq
- CLBR Nasdaq
- Market Cap
- DRUG 260.6M
- CLBR 230.6M
- IPO Year
- DRUG N/A
- CLBR 2023
- Fundamental
- Price
- DRUG $37.65
- CLBR $10.82
- Analyst Decision
- DRUG Strong Buy
- CLBR
- Analyst Count
- DRUG 4
- CLBR 0
- Target Price
- DRUG $84.33
- CLBR N/A
- AVG Volume (30 Days)
- DRUG 91.2K
- CLBR 430.0K
- Earning Date
- DRUG 12-31-2024
- CLBR 01-01-0001
- Dividend Yield
- DRUG N/A
- CLBR N/A
- EPS Growth
- DRUG N/A
- CLBR N/A
- EPS
- DRUG N/A
- CLBR N/A
- Revenue
- DRUG N/A
- CLBR N/A
- Revenue This Year
- DRUG N/A
- CLBR N/A
- Revenue Next Year
- DRUG N/A
- CLBR N/A
- P/E Ratio
- DRUG N/A
- CLBR $138.42
- Revenue Growth
- DRUG N/A
- CLBR N/A
- 52 Week Low
- DRUG $0.93
- CLBR $10.09
- 52 Week High
- DRUG $79.02
- CLBR $12.28
- Technical
- Relative Strength Index (RSI)
- DRUG 55.50
- CLBR 39.59
- Support Level
- DRUG $28.21
- CLBR $10.82
- Resistance Level
- DRUG $38.00
- CLBR $11.27
- Average True Range (ATR)
- DRUG 2.86
- CLBR 0.22
- MACD
- DRUG 0.45
- CLBR -0.02
- Stochastic Oscillator
- DRUG 96.42
- CLBR 3.53
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About CLBR Colombier Acquisition Corp. II
Colombier Acquisition Corp II is a blank check company.